Cargando…

Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes

The hexosamine biosynthetic pathway (HBP) culminates in the attachment of O-linked β-N-acetylglucosamine (O-GlcNAc) onto serine/threonine residues of target proteins. The HBP is regulated by several modulators, i.e. O-linked β-N-acetylglucosaminyl transferase (OGT) and β-N-acetylglucosaminidase (OGA...

Descripción completa

Detalles Bibliográficos
Autores principales: Coomer, Megan, Essop, M. Faadiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121314/
https://www.ncbi.nlm.nih.gov/pubmed/27896086
http://dx.doi.org/10.1016/j.ymgmr.2014.03.003
_version_ 1782469385438363648
author Coomer, Megan
Essop, M. Faadiel
author_facet Coomer, Megan
Essop, M. Faadiel
author_sort Coomer, Megan
collection PubMed
description The hexosamine biosynthetic pathway (HBP) culminates in the attachment of O-linked β-N-acetylglucosamine (O-GlcNAc) onto serine/threonine residues of target proteins. The HBP is regulated by several modulators, i.e. O-linked β-N-acetylglucosaminyl transferase (OGT) and β-N-acetylglucosaminidase (OGA) catalyze the addition and removal of O-GlcNAc moieties, respectively; while flux is controlled by the rate-limiting enzyme glutamine:fructose-6-phosphate amidotransferase (GFPT), transcribed by two genes, GFPT1 and GFPT2. Since increased HBP flux is glucose-responsive and linked to insulin resistance/type 2 diabetes onset, we hypothesized that diabetic individuals exhibit differential expression of HBP regulatory genes. Volunteers (n = 60; n = 20 Mixed Ancestry, n = 40 Caucasian) were recruited from Stellenbosch and Paarl (Western Cape, South Africa) and classified as control, pre- or diabetic according to fasting plasma glucose and HbA1c levels, respectively. RNA was purified from leukocytes isolated from collected blood samples and OGT, OGA, GFPT1 and GFPT2 expressions determined by quantitative real-time PCR. The data reveal lower OGA expression in diabetic individuals (P < 0.01), while pre- and diabetic subjects displayed attenuated OGT expression vs. controls (P < 0.01 and P < 0.001, respectively). Moreover, GFPT2 expression decreased in pre- and diabetic Caucasians vs. controls (P < 0.05 and P < 0.01, respectively). We also found ethnic differences, i.e. Mixed Ancestry individuals exhibited a 2.4-fold increase in GFPT2 expression vs. Caucasians, despite diagnosis (P < 0.01). Gene expression of HBP regulators differs between diabetic and non-diabetic individuals, together with distinct ethnic-specific gene profiles. Thus differential HBP gene regulation may offer diagnostic utility and provide candidate susceptibility genes for different ethnic groupings.
format Online
Article
Text
id pubmed-5121314
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-51213142016-11-28 Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes Coomer, Megan Essop, M. Faadiel Mol Genet Metab Rep Research Paper The hexosamine biosynthetic pathway (HBP) culminates in the attachment of O-linked β-N-acetylglucosamine (O-GlcNAc) onto serine/threonine residues of target proteins. The HBP is regulated by several modulators, i.e. O-linked β-N-acetylglucosaminyl transferase (OGT) and β-N-acetylglucosaminidase (OGA) catalyze the addition and removal of O-GlcNAc moieties, respectively; while flux is controlled by the rate-limiting enzyme glutamine:fructose-6-phosphate amidotransferase (GFPT), transcribed by two genes, GFPT1 and GFPT2. Since increased HBP flux is glucose-responsive and linked to insulin resistance/type 2 diabetes onset, we hypothesized that diabetic individuals exhibit differential expression of HBP regulatory genes. Volunteers (n = 60; n = 20 Mixed Ancestry, n = 40 Caucasian) were recruited from Stellenbosch and Paarl (Western Cape, South Africa) and classified as control, pre- or diabetic according to fasting plasma glucose and HbA1c levels, respectively. RNA was purified from leukocytes isolated from collected blood samples and OGT, OGA, GFPT1 and GFPT2 expressions determined by quantitative real-time PCR. The data reveal lower OGA expression in diabetic individuals (P < 0.01), while pre- and diabetic subjects displayed attenuated OGT expression vs. controls (P < 0.01 and P < 0.001, respectively). Moreover, GFPT2 expression decreased in pre- and diabetic Caucasians vs. controls (P < 0.05 and P < 0.01, respectively). We also found ethnic differences, i.e. Mixed Ancestry individuals exhibited a 2.4-fold increase in GFPT2 expression vs. Caucasians, despite diagnosis (P < 0.01). Gene expression of HBP regulators differs between diabetic and non-diabetic individuals, together with distinct ethnic-specific gene profiles. Thus differential HBP gene regulation may offer diagnostic utility and provide candidate susceptibility genes for different ethnic groupings. Elsevier 2014-04-17 /pmc/articles/PMC5121314/ /pubmed/27896086 http://dx.doi.org/10.1016/j.ymgmr.2014.03.003 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Research Paper
Coomer, Megan
Essop, M. Faadiel
Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title_full Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title_fullStr Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title_full_unstemmed Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title_short Differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
title_sort differential hexosamine biosynthetic pathway gene expression with type 2 diabetes
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121314/
https://www.ncbi.nlm.nih.gov/pubmed/27896086
http://dx.doi.org/10.1016/j.ymgmr.2014.03.003
work_keys_str_mv AT coomermegan differentialhexosaminebiosyntheticpathwaygeneexpressionwithtype2diabetes
AT essopmfaadiel differentialhexosaminebiosyntheticpathwaygeneexpressionwithtype2diabetes